|
Gene: PRRC2A |
Gene summary for PRRC2A |
Gene summary. |
Gene information | Species | Human | Gene symbol | PRRC2A | Gene ID | 7916 |
Gene name | proline rich coiled-coil 2A | |
Gene Alias | BAT2 | |
Cytomap | 6p21.33 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A1U9X974 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7916 | PRRC2A | HTA11_347_2000001011 | Human | Colorectum | AD | 4.06e-06 | 2.64e-01 | -0.1954 |
7916 | PRRC2A | HTA11_83_2000001011 | Human | Colorectum | SER | 6.53e-03 | 2.48e-01 | -0.1526 |
7916 | PRRC2A | HTA11_696_2000001011 | Human | Colorectum | AD | 3.43e-08 | 3.90e-01 | -0.1464 |
7916 | PRRC2A | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.74e-06 | 4.53e-01 | -0.059 |
7916 | PRRC2A | HTA11_866_3004761011 | Human | Colorectum | AD | 3.73e-05 | 3.40e-01 | 0.096 |
7916 | PRRC2A | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.98e-04 | 3.61e-01 | 0.0674 |
7916 | PRRC2A | HTA11_11156_2000001011 | Human | Colorectum | AD | 3.83e-03 | 6.30e-01 | 0.0397 |
7916 | PRRC2A | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.60e-07 | 4.69e-01 | 0.0588 |
7916 | PRRC2A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.60e-12 | 5.96e-01 | 0.3859 |
7916 | PRRC2A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.17e-03 | 3.39e-01 | 0.3005 |
7916 | PRRC2A | A015-C-203 | Human | Colorectum | FAP | 2.12e-03 | -8.91e-03 | -0.1294 |
7916 | PRRC2A | A015-C-104 | Human | Colorectum | FAP | 4.94e-04 | -9.28e-02 | -0.1899 |
7916 | PRRC2A | A002-C-116 | Human | Colorectum | FAP | 2.54e-04 | -1.26e-01 | -0.0452 |
7916 | PRRC2A | LZE4T | Human | Esophagus | ESCC | 5.31e-15 | 4.63e-01 | 0.0811 |
7916 | PRRC2A | LZE5T | Human | Esophagus | ESCC | 5.32e-03 | 1.90e-01 | 0.0514 |
7916 | PRRC2A | LZE7T | Human | Esophagus | ESCC | 2.08e-18 | 1.13e+00 | 0.0667 |
7916 | PRRC2A | LZE8T | Human | Esophagus | ESCC | 2.02e-08 | 3.51e-01 | 0.067 |
7916 | PRRC2A | LZE20T | Human | Esophagus | ESCC | 9.79e-09 | 4.72e-01 | 0.0662 |
7916 | PRRC2A | LZE22D1 | Human | Esophagus | HGIN | 1.27e-03 | 1.01e-01 | 0.0595 |
7916 | PRRC2A | LZE22T | Human | Esophagus | ESCC | 4.80e-03 | 3.37e-01 | 0.068 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRRC2A | SNV | Missense_Mutation | c.6265N>T | p.Arg2089Cys | p.R2089C | P48634 | protein_coding | deleterious_low_confidence(0) | benign(0.001) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PRRC2A | SNV | Missense_Mutation | novel | c.239C>A | p.Pro80Gln | p.P80Q | P48634 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRRC2A | SNV | Missense_Mutation | rs751376148 | c.2272N>T | p.Arg758Cys | p.R758C | P48634 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRRC2A | SNV | Missense_Mutation | novel | c.1172N>T | p.Ala391Val | p.A391V | P48634 | protein_coding | deleterious(0.01) | probably_damaging(0.978) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
PRRC2A | SNV | Missense_Mutation | novel | c.1499N>A | p.Pro500His | p.P500H | P48634 | protein_coding | deleterious(0.01) | benign(0.014) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRRC2A | SNV | Missense_Mutation | novel | c.680N>G | p.His227Arg | p.H227R | P48634 | protein_coding | tolerated(0.48) | benign(0) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRRC2A | SNV | Missense_Mutation | rs369956824 | c.2908N>A | p.Glu970Lys | p.E970K | P48634 | protein_coding | deleterious_low_confidence(0.03) | benign(0.012) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
PRRC2A | SNV | Missense_Mutation | novel | c.3572N>A | p.Ser1191Tyr | p.S1191Y | P48634 | protein_coding | deleterious(0.01) | benign(0.254) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
PRRC2A | SNV | Missense_Mutation | c.4752N>A | p.Phe1584Leu | p.F1584L | P48634 | protein_coding | tolerated(0.34) | benign(0.003) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
PRRC2A | SNV | Missense_Mutation | novel | c.2800N>T | p.Arg934Cys | p.R934C | P48634 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-EY-A1GD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7916 | PRRC2A | NA | carbamazepine | CARBAMAZEPINE | 16538176 | |
7916 | PRRC2A | NA | carboplatin | CARBOPLATIN | 31616045 | |
7916 | PRRC2A | NA | gemcitabine | GEMCITABINE | 31616045 |
Page: 1 |